PatientsVille.com Logo

MUSCULAR WEAKNESS and Trazodone

PatientsVille

MUSCULAR WEAKNESS Symptoms and Causes

Myasthenia gravis is a disease that causes weakness in your voluntary muscles. These are the muscles that you control. For example, you may have weakness in the muscles for eye movement, facial expressions, and swallowing. You can also have weakness in other muscles. This weakness gets worse with activity, and better with rest.

Myasthenia gravis is an autoimmune disease. Your body's immune system makes antibodies that block or change some of the nerve signals to your muscles. This makes your muscles weaker.

Other conditions can cause muscle weakness, so myasthenia gravis can be hard to diagnose. Tests used to make a diagnosis include blood, nerve, muscle, and imaging tests.

With treatment, the muscle weakness often gets much better. Medicines can help improve nerve-to-muscle messages and make muscles stronger. Other drugs keep your body from making so many abnormal antibodies. These medicines can have major side effects, so they should be used carefully. There are also treatments which filter abnormal antibodies from the blood or add healthy antibodies from donated blood. Sometimes, surgery to take out the thymus gland helps.

Some people with myasthenia gravis go into remission. This means that they do not have symptoms. The remission is usually temporary, but sometimes it can be permanent.

NIH: National Institute of Neurological Disorders and Stroke

Check out the latest treatments for MUSCULAR WEAKNESS

MUSCULAR WEAKNESS treatment research studies

Trazodone clinical trials, surveys and public health registries


Find Drug Side Effect reports



Trazodone Side Effects

Completed Suicide (190)
Priapism (134)
Insomnia (129)
Dizziness (118)
Nausea (113)
Depression (109)
Respiratory Arrest (108)
Headache (101)
Pain (100)
Vomiting (94)
Cardiac Arrest (94)
Fatigue (91)
Anxiety (89)
Dyspnoea (89)
Confusional State (88)
Serotonin Syndrome (86)
Overdose (86)
Diarrhoea (80)
Suicide Attempt (79)
Asthenia (68)
Suicidal Ideation (34)
Fall (33)
Somnolence (30)
Feeling Abnormal (30)
Convulsion (29)
Arthralgia (28)
Toxicity To Various Agents (28)
Malaise (28)
Pain In Extremity (28)
Rash (28)
Weight Increased (27)
Hypotension (27)
Gait Disturbance (26)
Product Quality Issue (26)
Intentional Overdose (26)
Myalgia (26)
Constipation (25)
Tremor (24)
Loss Of Consciousness (23)
Condition Aggravated (23)
Muscle Spasms (22)
Back Pain (22)
Cardio-respiratory Arrest (22)
Electrocardiogram Qt Prolonged (21)
Pyrexia (21)
Palpitations (21)
Hallucination (20)
Amnesia (20)
Erectile Dysfunction (19)
Paraesthesia (19)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

<b><span style='font-weight: normal;'><b>After 6 weeks of oral lamisil I experienced</b>eczema, muscle weakness, asthma, bloody bowels, lower abdominal pain, dizziness, extreme f

<strong></strong><span style='color: #ffa500;'>I am experiencing severe muscular <span style='color: #0000ff;'>pain/muscle tighteningin the diaphragm and sometimes &

<strong>I am on Cipralex now for about 2-3 months -10mg in the morning for depression, and now am experiencing chronic muscle weakness, chronic pain in both wrists and left hip, chronic fatigue, nausea, constant dizziness, tremors/shaky, restle

2 patients given thiocolchicoside reported of muscular stiffness,uneasiness,insomnia,breathlessness and feeling of restlessness, 2 out of 5 patients have reported such experiences after consuming thiocolchicoside.i strongly recommend to withdraw this

Afeccion cardiaca,pues a pesar de hacer ejercicio se me bloquearon las arterias,por mucho colesterol y tuvieron que hacerme un cateterismo, tengo once aos de que me detectaron la enfermedad. He perdido masa muscular pero nado ycamino dos o tres ve

After 18 months, great fatigue and muscular pain. Is this due to Intragam? consultant thinks I'm being fussy

After a 1 week course of Trimethoprim 200mg. I developed mild thrush on day3, muscle weakness for 1 day on the day after completion of the course and, 3 days after completion generalised urticaria. Not sure if this is delayed sensitivity but I assu

After finnishing the dose for Artequin I started feeling, body twitching, weakness,dizzness, body cramps, headache, neck pain, sore joints and now am at my sixth day after the dose and still experiencing the side effects..

After my first injection on Friday three weeks ago I experienced numbness and weakness Sunday night after injection along with a fever and night sweats. Went back to doctor on Tuesday and had an ultrasound to see if blockages or blood clots everythin

After takin tablets, i am feelimg somewhat uneasyness, feeling weakness, food intake is reduced

MUSCULAR WEAKNESS Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Efficacy and Safety of Risperidone and Trazodone Monotherapy and Combination Therapy in Critically Ill Patients With Delirium
Conditions: Delirium;   Agitation
Interventions: Drug: Risperidone;   Drug: Trazodone;   Drug: Placebo
Outcome Measures: The number of days patients are without delirium during the study period (delirium-free days);   Daily prevalence of delirium as indicated by a positive Confusion Assessment Method in the ICU (CAM-ICU);   Resolution of delirium as indicated by a negative Confusion Assessment Method in the ICU (CAM-ICU) for more than 24 hours;   The number of patients who require rescue medications, the type of rescue medications utilized, and the amount of rescue medications per day;   The number of patients who receive sedative agents, amount of midazolam equivalents per day, and the number of days in which patients receive a sedative agent;   The number of patients who receive pain medications, amount of fentanyl equivalents per day, and the number of days in which patients receive a pain medication;   The number of hours spent agitated (RASS score between +4 and +2) as a percent of the time that the study drug was administered;   The number of hours spent excessively sedated or in a coma state (RASS score between -4 to -5) as a percent of the time that the study drug was administered;   The duration of mechanical ventilation from initial intubation to extubation as long as the patient remained extubated for more than 48 hours.;   The number of days that the patients were alive and breathing without assistance during the study period (ventilator-free days);   The number of episodes and number of patients who experience clinically significant QTc prolongation (≥ 500 msec or an increase of more than 60 msec from baseline);   The number of episodes and number of patients who experience clinically significant extrapyramidal effects (as evidenced by a positive Simpson-Angus Scale Score);   All-cause mortality and 28-day mortality
2 Unknown  A Clinical Study of Trazodone Hydrochloride Prolonged-Release Tablets for Treatment of Depression
Condition: Depression
Interventions: Drug: Trazodone;   Drug: Placebo
Outcome Measures: Change in Hamilton Depression Rating Scale-17 score;   Changes in HAMA-14 score;   CGI-Severity of illness and CGI-Global improvement;   Changes in evaluation of sleep quality and sexual dysfunction;   Rate changes of responders/patients
3 Recruiting Study of Trazodone & Cognitive Behavioral Therapy to Treat Insomnia
Condition: Insomnia
Interventions: Drug: Trazodone;   Behavioral: Cognitive Behavioral Therapy
Outcome Measures: Change from Baseline in objective sleep duration at 9 months;   Change from Baseline in Subjective Severity of Sleep Disturbance & Subjective Sleep Duration at 9 months
4 Recruiting The Effects of Trazodone on Sleep Apnea Severity
Condition: Sleep Apnea, Obstructive
Interventions: Drug: Placebo pill;   Drug: Trazodone
Outcome Measures: Apnea-Hypopnea Index;   Arousal threshold
5 Unknown  Comparison of the Pharmacokinetics of Three Generic Medications and Their Respective Brand Preparations
Condition: Healthy
Interventions: Drug: Trazodone;   Drug: Quetiapine;   Drug: Pindolol;   Procedure: Blood Collection
Outcome Measure: Plasma levels of Medication
6 Recruiting Algorithm Guided Treatment Strategies for Major Depressive Disorder
Condition: Major Depressive Disorder
Interventions: Drug: Escitalopram;   Drug: Mirtazapine;   Other: modified electroconvulsive therapy;   Other: repetitive transcranial magnetic stimulation;   Drug: Fluoxetine;   Drug: Citalopram;   Drug: Paroxetine;   Drug: Sertraline;   Drug: Fluvoxamine;   Drug: Venlafaxine;   Drug: Duloxetine;   Drug: Bupropion;   Drug: Trazodone
Outcome Measures: Remission defined as endpoint 17-item Hamilton Rating Scale for Depression (HRSD-17) total score ≤ 7;   Remission defined as endpoint the Quick Inventory of Depressive Symptomatology (16-item) (QIDS-SR16) total score ≤ 5;   Frequency and intensity of adverse events;   Quality of life
7 Recruiting Development of Pharmacogenomic Method to Predict Antidepressant Responsiveness
Conditions: Depression;   Antidepressant Drug Adverse Reaction
Interventions: Drug: SSRI class antidepressant;   Drug: non-SSRI class antidepressant
Outcome Measures: all pharmacogenetic and biological marker variables cause drug response;   all clinical cause drug response
8 Recruiting Sequenced Therapies for Comorbid and Primary Insomnias
Conditions: Insomnia Comorbid to Psychiatric Disorder;   Primary Insomnia
Interventions: Behavioral: Behavioral Insomnia Therapy;   Drug: Zolpidem;   Drug: Trazodone;   Behavioral: Cognitive Therapy
Outcome Measure: Insomnia Severity Index- Change from Baseline (Remission)
9 Recruiting Interpersonal Psychotherapy for Treatment Resistant Depression
Condition: Treatment Resistant Depression
Interventions: Other: IPT+ antidepressant drugs;   Drug: fluoxetine;   Drug: sertraline;   Drug: paroxetine;   Drug: Citalopram;   Drug: escitalopram;   Drug: fluvoxamine;   Drug: Venlafaxine;   Drug: Duloxetine;   Drug: Bupropion;   Drug: Lithium;   Drug: Risperidone;   Drug: tranylcypromine;   Drug: Imipramine;   Drug: amitriptyline;   Drug: Clomipramine;   Drug: nortriptyline;   Drug: Trazodone;   Drug: Mirtazapine;   Drug: sulpiride
Outcome Measures: Hamilton Depression Scale (HAM-D) - continuous;   Beck depression Inventory (BDI)
10 Recruiting Study Comparing 3 Different Treatments for Arthritis of the Lower Back (Lumbar Spinal Stenosis)
Condition: Lumbar Spinal Stenosis
Interventions: Drug: NSAIDs; adjunctive analgesics; adjunctive anti-depressants;   Procedure: Lumbar epidural injection;   Other: Joint Mobilizations (spine, sacroiliac, hip);   Other: Individualized exercises: clinical setting;   Other: Group Exercise: community setting
Outcome Measures: Swiss Spinal Stenosis Questionnaire Score;   Self Paced Walking Test
11 Recruiting The Effects of Cannabinoid on Patients With Non-GERD Related Non Cardiac Chest Pain
Condition: Chest Pain
Interventions: Drug: Marinol;   Drug: Placebo
Outcome Measures: Frequency of chest pain episodes;   Frequency of chest pain in treatment group vs baseline;   Intensity of chest pain episodes;   Sensory thresholds for first sensation;   Frequency of reactive esophageal contractions;   Amplitude of reactive esophageal contractions;   Area under the curve of reactive esophageal contractions;   Duration of chest pain episodes;   Sensory thresholds for discomfort;   Sensory thresholds for pain